233 related articles for article (PubMed ID: 30392011)
21. Predictive molecular biomarkers for determining neoadjuvant chemosensitivity in muscle invasive bladder cancer.
Murphy N; Shih AJ; Shah P; Yaskiv O; Khalili H; Liew A; Lee AT; Zhu XH
Oncotarget; 2022 Nov; 13():1188-1200. PubMed ID: 36322407
[TBL] [Abstract][Full Text] [Related]
22. Circulating tumor DNA as a Predictive and Prognostic Biomarker in the Perioperative Treatment of Muscle-invasive Bladder Cancer: A Systematic Review.
Crupi E; de Padua TC; Marandino L; Raggi D; Dyrskjøt L; Spiess PE; Sonpavde GP; Kamat AM; Necchi A
Eur Urol Oncol; 2024 Feb; 7(1):44-52. PubMed ID: 37330413
[TBL] [Abstract][Full Text] [Related]
23. Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma.
Pokuri VK; Syed JR; Yang Z; Field EP; Cyriac S; Pili R; Levine EG; Azabdaftari G; Trump DL; Guru K; George S
Clin Genitourin Cancer; 2016 Feb; 14(1):e59-65. PubMed ID: 26508364
[TBL] [Abstract][Full Text] [Related]
24. Liquid Biopsies to Select Patients for Perioperative Chemotherapy in Muscle-invasive Bladder Cancer: A Systematic Review.
de Kruijff IE; Beije N; Martens JWM; de Wit R; Boormans JL; Sleijfer S
Eur Urol Oncol; 2021 Apr; 4(2):204-214. PubMed ID: 32059957
[TBL] [Abstract][Full Text] [Related]
25. Sentinel node detection in muscle-invasive urothelial bladder cancer is feasible after neoadjuvant chemotherapy in all pT stages, a prospective multicenter report.
Rosenblatt R; Johansson M; Alamdari F; Sidiki A; Holmström B; Hansson J; Vasko J; Marits P; Gabrielsson S; Riklund K; Winqvist O; Sherif A
World J Urol; 2017 Jun; 35(6):921-927. PubMed ID: 27738804
[TBL] [Abstract][Full Text] [Related]
26. Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209.
Kitamura H; Tsukamoto T; Shibata T; Masumori N; Fujimoto H; Hirao Y; Fujimoto K; Kitamura Y; Tomita Y; Tobisu K; Niwakawa M; Naito S; Eto M; Kakehi Y;
Ann Oncol; 2014 Jun; 25(6):1192-8. PubMed ID: 24669010
[TBL] [Abstract][Full Text] [Related]
27. Neoadjuvant therapy for muscle-invasive bladder cancer: Current clinical scenario, future perspectives, and unsolved questions.
Ruiz de Porras V; Pardo JC; Etxaniz O; Font A
Crit Rev Oncol Hematol; 2022 Oct; 178():103795. PubMed ID: 35988856
[TBL] [Abstract][Full Text] [Related]
28. Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer.
Jiang DM; Jiang H; Chung PWM; Zlotta AR; Fleshner NE; Bristow RG; Berlin A; Kulkarni GS; Alimohamed NS; Lo G; Sridhar SS
Clin Genitourin Cancer; 2019 Feb; 17(1):38-45. PubMed ID: 30686350
[TBL] [Abstract][Full Text] [Related]
29. Copper Transporter-CTR1 Expression and Pathological Outcomes in Platinum-treated Muscle-invasive Bladder Cancer Patients.
Kilari D; Iczkowski KA; Pandya C; Robin AJ; Messing EM; Guancial E; Kim ES
Anticancer Res; 2016 Feb; 36(2):495-501. PubMed ID: 26851002
[TBL] [Abstract][Full Text] [Related]
30. RNA Expression of DNA Damage Response Genes in Muscle-Invasive Bladder Cancer: Influence on Outcome and Response to Adjuvant Cisplatin-Based Chemotherapy.
Herrmann J; Schmidt H; Nitschke K; Weis CA; Nuhn P; von Hardenberg J; Michel MS; Erben P; Worst TS
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33919527
[TBL] [Abstract][Full Text] [Related]
31. Perioperative chemotherapy for muscle invasive bladder cancer.
Rudzinski JK; Basappa NS; North S
Curr Opin Support Palliat Care; 2015 Sep; 9(3):249-54. PubMed ID: 26125306
[TBL] [Abstract][Full Text] [Related]
32. Maspin enhances cisplatin chemosensitivity in bladder cancer T24 and 5637 cells and correlates with prognosis of muscle-invasive bladder cancer patients receiving cisplatin based neoadjuvant chemotherapy.
Chen J; Wang L; Tang Y; Gong G; Liu L; Chen M; Chen Z; Cui Y; Li C; Cheng X; Qi L; Zu X
J Exp Clin Cancer Res; 2016 Jan; 35():2. PubMed ID: 26733306
[TBL] [Abstract][Full Text] [Related]
33. ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscle-invasive bladder cancer.
Sonpavde G; Necchi A; Gupta S; Steinberg GD; Gschwend JE; Van Der Heijden MS; Garzon N; Ibrahim M; Raybold B; Liaw D; Rutstein M; Galsky MD
Future Oncol; 2020 Jan; 16(2):4359-4368. PubMed ID: 31823654
[TBL] [Abstract][Full Text] [Related]
34. Divergent Biological Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer.
Seiler R; Gibb EA; Wang NQ; Oo HZ; Lam HM; van Kessel KE; Voskuilen CS; Winters B; Erho N; Takhar MM; Douglas J; Vakar-Lopez F; Crabb SJ; van Rhijn BWG; Fransen van de Putte EE; Zwarthoff EC; Thalmann GN; Davicioni E; Boormans JL; Dall'Era M; van der Heijden MS; Wright JL; Black PC
Clin Cancer Res; 2019 Aug; 25(16):5082-5093. PubMed ID: 30224344
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant chemotherapy with docetaxel and cisplatin in patients with high-risk resectable bladder carcinoma: long term results.
Bamias A; Deliveliotis C; Karayiannis A; Varkarakis I; Zervas I; Pantazopoulos D; Gika D; Dimopoulos MA
Eur Urol; 2004 Sep; 46(3):344-50; discussion 350-1. PubMed ID: 15306106
[TBL] [Abstract][Full Text] [Related]
36. Neoadjuvant chemotherapy administration and time to cystectomy for muscle-invasive bladder cancer: An evaluation of transitions between academic and community settings.
Rose TL; Deal AM; Basch E; Godley PA; Rathmell WK; Kim WY; Whang YE; Dunn MW; Wang A; Chen RC; Nielsen ME; Pruthi RS; Wallen EM; Woods ME; Smith AB; Milowsky MI
Urol Oncol; 2015 Sep; 33(9):386.e1-6. PubMed ID: 26122712
[TBL] [Abstract][Full Text] [Related]
37. [ypT0N0 after neoadjuvant chemotherapy and cystectomy for muscle-invasive bladder cancer: Incidence and prognosis. A review from the Bladder group of the French Committee of Oncology].
Pignot G; Houédé N; Roumiguié M; Audenet F; Brunelle S; Colin P; Compérat E; Larré S; Masson-Lecomte A; Neuzillet Y; Xylinas E; Méjean A; Rouprêt M;
Prog Urol; 2018 Oct; 28(12):567-574. PubMed ID: 30205925
[TBL] [Abstract][Full Text] [Related]
38. Low Pretreatment Neutrophil-to-Lymphocyte Ratio Predicts for Good Outcomes in Patients Receiving Neoadjuvant Chemotherapy Before Radical Cystectomy for Muscle Invasive Bladder Cancer.
Buisan O; Orsola A; Areal J; Font A; Oliveira M; Martinez R; Ibarz L
Clin Genitourin Cancer; 2017 Feb; 15(1):145-151.e2. PubMed ID: 27364982
[TBL] [Abstract][Full Text] [Related]
39. Predictive Biomarkers of Response to Neoadjuvant Therapy in Muscle Invasive Bladder Cancer.
Nikkola J; Black P
Methods Mol Biol; 2023; 2684():229-247. PubMed ID: 37410238
[TBL] [Abstract][Full Text] [Related]
40. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer.
Rosenblatt R; Sherif A; Rintala E; Wahlqvist R; Ullén A; Nilsson S; Malmström PU;
Eur Urol; 2012 Jun; 61(6):1229-38. PubMed ID: 22189383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
